These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 21420384

  • 1. Correlation between time-dependent inhibition of human farnesyl pyrophosphate synthase and blockade of mevalonate pathway by nitrogen-containing bisphosphonates in cultured cells.
    Räikkönen J, Taskinen M, Dunford JE, Mönkkönen H, Auriola S, Mönkkönen J.
    Biochem Biophys Res Commun; 2011 Apr 22; 407(4):663-7. PubMed ID: 21420384
    [Abstract] [Full Text] [Related]

  • 2. Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.
    Räikkönen J, Mönkkönen H, Auriola S, Mönkkönen J.
    Biochem Pharmacol; 2010 Mar 01; 79(5):777-83. PubMed ID: 19819230
    [Abstract] [Full Text] [Related]

  • 3. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
    Mitrofan LM, Pelkonen J, Mönkkönen J.
    Bone; 2009 Dec 01; 45(6):1153-60. PubMed ID: 19699819
    [Abstract] [Full Text] [Related]

  • 4. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V, Fournier PG, Bellahcène A, Benzaïd I, Mönkkönen H, Colombel M, Ebetino FH, Castronovo V, Clézardin P.
    Bone; 2011 Feb 01; 48(2):259-66. PubMed ID: 20920623
    [Abstract] [Full Text] [Related]

  • 5. Bisphosphonates: the first 40 years.
    Russell RG.
    Bone; 2011 Jul 01; 49(1):2-19. PubMed ID: 21555003
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid-induced IPP/ApppI production in vivo.
    Mönkkönen H, Ottewell PD, Kuokkanen J, Mönkkönen J, Auriola S, Holen I.
    Life Sci; 2007 Sep 08; 81(13):1066-70. PubMed ID: 17850825
    [Abstract] [Full Text] [Related]

  • 7. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
    Dunford JE, Kwaasi AA, Rogers MJ, Barnett BL, Ebetino FH, Russell RG, Oppermann U, Kavanagh KL.
    J Med Chem; 2008 Apr 10; 51(7):2187-95. PubMed ID: 18327899
    [Abstract] [Full Text] [Related]

  • 8. Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry.
    Jauhiainen M, Mönkkönen H, Räikkönen J, Mönkkönen J, Auriola S.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct 01; 877(27):2967-75. PubMed ID: 19665949
    [Abstract] [Full Text] [Related]

  • 9. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.
    van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S.
    Biochem Biophys Res Commun; 1999 Oct 14; 264(1):108-11. PubMed ID: 10527849
    [Abstract] [Full Text] [Related]

  • 10. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.
    Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W.
    ChemMedChem; 2006 Feb 14; 1(2):267-73. PubMed ID: 16892359
    [Abstract] [Full Text] [Related]

  • 11. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I, Mönkkönen H, Bonnelye E, Mönkkönen J, Clézardin P.
    Clin Cancer Res; 2012 Nov 15; 18(22):6249-59. PubMed ID: 23032740
    [Abstract] [Full Text] [Related]

  • 12. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH, Hogan AM, Sun S, Tsoumpra MK, Duan X, Triffitt JT, Kwaasi AA, Dunford JE, Barnett BL, Oppermann U, Lundy MW, Boyde A, Kashemirov BA, McKenna CE, Russell RG.
    Bone; 2011 Jul 15; 49(1):20-33. PubMed ID: 21497677
    [Abstract] [Full Text] [Related]

  • 13. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.
    Räikkönen J, Crockett JC, Rogers MJ, Mönkkönen H, Auriola S, Mönkkönen J.
    Br J Pharmacol; 2009 Jun 15; 157(3):427-35. PubMed ID: 19371349
    [Abstract] [Full Text] [Related]

  • 14. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.
    Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, Mönkkönen J.
    Br J Pharmacol; 2006 Feb 15; 147(4):437-45. PubMed ID: 16402039
    [Abstract] [Full Text] [Related]

  • 15. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.
    Ann N Y Acad Sci; 2007 Nov 15; 1117():209-57. PubMed ID: 18056045
    [Abstract] [Full Text] [Related]

  • 16. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ.
    J Pharmacol Exp Ther; 2001 Feb 15; 296(2):235-42. PubMed ID: 11160603
    [Abstract] [Full Text] [Related]

  • 17. Bisphosphonates: from bench to bedside.
    Russell RG.
    Ann N Y Acad Sci; 2006 Apr 15; 1068():367-401. PubMed ID: 16831938
    [Abstract] [Full Text] [Related]

  • 18. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
    Thompson K, Rogers MJ.
    J Bone Miner Res; 2004 Feb 15; 19(2):278-88. PubMed ID: 14969398
    [Abstract] [Full Text] [Related]

  • 19. Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay.
    Glickman JF, Schmid A.
    Assay Drug Dev Technol; 2007 Apr 15; 5(2):205-14. PubMed ID: 17477829
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
    Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS.
    Eur J Pharmacol; 2007 Sep 10; 570(1-3):27-37. PubMed ID: 17640631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.